What is HC Wainwright’s Estimate for Humacyte Q3 Earnings?

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at HC Wainwright lowered their Q3 2025 EPS estimates for Humacyte in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.18) per share for the quarter, down from their prior estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at $0.03 EPS.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09). The firm had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.94 million.

A number of other research firms also recently weighed in on HUMA. Wall Street Zen raised shares of Humacyte from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. TD Cowen dropped their price target on shares of Humacyte from $5.00 to $3.50 and set a “buy” rating on the stock in a research note on Tuesday. Benchmark decreased their price objective on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Monday, August 11th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Humacyte currently has an average rating of “Moderate Buy” and an average price target of $10.64.

Humacyte Stock Performance

NASDAQ HUMA opened at $1.88 on Thursday. Humacyte has a 1-year low of $1.15 and a 1-year high of $7.48. The company has a current ratio of 2.45, a quick ratio of 3.28 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $291.63 million, a PE ratio of -4.18 and a beta of 1.90. The firm’s fifty day simple moving average is $2.32 and its 200-day simple moving average is $2.46.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Heights Capital Management Inc. bought a new stake in Humacyte during the first quarter valued at about $6,863,000. Woodline Partners LP boosted its holdings in Humacyte by 38.7% during the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock valued at $6,735,000 after acquiring an additional 1,101,198 shares during the period. CenterBook Partners LP boosted its holdings in Humacyte by 141.1% during the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after acquiring an additional 2,007,743 shares during the period. RA Capital Management L.P. bought a new stake in Humacyte during the first quarter valued at about $5,648,000. Finally, Geode Capital Management LLC boosted its holdings in Humacyte by 33.4% during the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after acquiring an additional 738,142 shares during the period. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.